Cyclosporine, combination immunosuppression, and posttransplant diabetes mellitus.
Boudreaux
J P
JP
Department of Surgery, University of Minnesota Hospitals and Clinics.
McHugh
L
L
Canafax
D M
DM
Asher
N
N
Sutherland
D E
DE
Payne
W
W
Simmons
R L
RL
Najarian
J S
JS
Fryd
D S
DS
D000328:Adult; D000367:Age Factors; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003524:Cyclosporins / Q000009:adverse effects* / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000139:chemically induced / Q000209:etiology*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D011897:Random Allocation
D000961:Antilymphocyte Serum; D003524:Cyclosporins; D001379:Azathioprine; D011241:Prednisone